These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 11598040

  • 1. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
    Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ.
    Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
    [Abstract] [Full Text] [Related]

  • 2. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ.
    J Clin Invest; 1996 Nov 15; 98(10):2308-14. PubMed ID: 8941648
    [Abstract] [Full Text] [Related]

  • 3. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
    Baker CJ, Rench MA, Paoletti LC, Edwards MS.
    Vaccine; 2007 Jan 02; 25(1):55-63. PubMed ID: 16919857
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
    Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS.
    J Infect Dis; 2003 Jul 01; 188(1):66-73. PubMed ID: 12825173
    [Abstract] [Full Text] [Related]

  • 5. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
    Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL.
    J Infect Dis; 2004 Mar 15; 189(6):1103-12. PubMed ID: 14999615
    [Abstract] [Full Text] [Related]

  • 6. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL, Ferrieri P, Edwards MS, Ewell M, Ferris D, Fine P, Carey V, Meyn L, Hoagland D, Kasper DL, Paoletti LC, Hill H, Baker CJ.
    Clin Infect Dis; 2019 May 30; 68(12):2079-2086. PubMed ID: 30281066
    [Abstract] [Full Text] [Related]

  • 7. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
    Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME, Kasper DL.
    J Infect Dis; 2000 Oct 30; 182(4):1129-38. PubMed ID: 10979909
    [Abstract] [Full Text] [Related]

  • 8. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Vaccine; 2000 Nov 22; 19(7-8):850-61. PubMed ID: 11115709
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL.
    J Infect Dis; 1999 Jan 22; 179(1):142-50. PubMed ID: 9841833
    [Abstract] [Full Text] [Related]

  • 10. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
    Palazzi DL, Rench MA, Edwards MS, Baker CJ.
    J Infect Dis; 2004 Aug 01; 190(3):558-64. PubMed ID: 15243932
    [Abstract] [Full Text] [Related]

  • 11. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Infect Immun; 2000 Oct 01; 68(10):5749-55. PubMed ID: 10992481
    [Abstract] [Full Text] [Related]

  • 12. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C, Kasper DL, Paoletti LC, Madoff LC.
    Infect Immun; 1999 May 01; 67(5):2491-6. PubMed ID: 10225912
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA, Cutland CL, Jose L, Koen A, Govender N, Wittke F, Olugbosi M, Meulen AS, Baker S, Dull PM, Narasimhan V, Slobod K.
    Lancet Infect Dis; 2016 Aug 01; 16(8):923-34. PubMed ID: 27139805
    [Abstract] [Full Text] [Related]

  • 14. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.
    Baker CJ, Rench MA, McInnes P.
    Vaccine; 2003 Jul 28; 21(24):3468-72. PubMed ID: 12850362
    [Abstract] [Full Text] [Related]

  • 15. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits.
    Paoletti LC, Guttormsen HK, Christian MS, Hoberman AM, McInnes P.
    Hum Vaccin; 2008 Jul 28; 4(6):435-43. PubMed ID: 18443428
    [Abstract] [Full Text] [Related]

  • 16. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
    Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC.
    Infect Immun; 2007 Jul 28; 75(7):3455-61. PubMed ID: 17470542
    [Abstract] [Full Text] [Related]

  • 17. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.
    Paoletti LC, Pinel J, Kennedy RC, Kasper DL.
    J Infect Dis; 2000 Feb 28; 181(2):653-8. PubMed ID: 10669351
    [Abstract] [Full Text] [Related]

  • 18. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
    Palmeiro JK, De Carvalho NS, Botelho AC, Fracalanzza SE, Madeira HM, Dalla-Costa LM.
    Vaccine; 2011 May 12; 29(21):3729-30. PubMed ID: 21414381
    [Abstract] [Full Text] [Related]

  • 19. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
    Yang HH, Mascuch SJ, Madoff LC, Paoletti LC.
    Clin Vaccine Immunol; 2008 Jul 12; 15(7):1035-41. PubMed ID: 18463225
    [Abstract] [Full Text] [Related]

  • 20. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Wallerström G, Holmgren J.
    Vaccine; 2001 May 14; 19(25-26):3360-8. PubMed ID: 11348699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.